Merkel cell carcinoma (MCC) – neuroendocrine skin cancer

Dudzisz-Śledź, Monika; Zdzienicki, Marcin; Rutkowski, Piotr

doi:10.5603/njo.2019.0022

Cited by 6 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the literature, occult lymph node disease is present in up to 50% of patients [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]; thus, SLNB should be performed in all patients. We confirmed the value of SLNB by showing that patients with clinically less-suspicious lymph nodes who have not undergone the SLNB had over 5-times higher risk of disease recurrence and nearly 2.5 times higher risk of death.…”

Section: Discussionmentioning

confidence: 99%

“…Approximately 50–65% of MCC patients have localized disease at presentation, and 25–50% have regional metastases [ 3 , 4 ]. Subclinical nodal metastases are present in 30–50% of patients with primary MCC, with an increased presence in patients with a primary tumor greater than 1 cm in diameter [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. The sentinel lymph node biopsy (SLNB) is recommended in cases without clinical nodal involvement.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Locally Advanced Merkel Cell Carcinoma—A Multi-Center Study

Dudzisz-Śledź

Sobczuk

Kozak

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with a high risk of recurrence and poor prognosis. The treatment of locally advanced disease involves surgery and radiotherapy. To analyze real-life treatment patterns and clinical outcomes, we conducted a retrospective analysis of data from 161 MCC patients treated with curative intent in four oncological centers in Poland. The median age at diagnosis was 72 years (30–94); 49.7% were male. Lymph node (LN) involvement at diagnosis was found in 26.9% of patients. Sentinel lymph node biopsy (SLNB) was performed in 36.5% of patients (positive in 10.5%), and 51.9% of patients received perioperative treatment. The relapse rate was 38.3%. With the median follow-up of 2.3 years, the median disease-free survival (DFS) was not reached, and the 1-year rate was 65%. The negative independent risk factors for DFS were male gender, metastases in LN at diagnosis, no SLNB in patients without clinical nodal metastases, and no perioperative radiotherapy. The estimated median overall survival (OS) was 6.9 years (95%CI 4.64–9.15). The negative independent risk factors for OS were male gender, age above 70, metastases in LN at diagnosis, and no SLNB in patients without clinical nodal metastases. Our results confirm that the MCC treatment should be conducted in an experienced multidisciplinary team; however, the outcomes are still unsatisfactory.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Treatment of Locally Advanced Merkel Cell Carcinoma—A Multi-Center Study

Dudzisz-Śledź

Sobczuk

Kozak

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a second-linesetting, RR rates range from 23% to 45% with a median PFS of 2 months and duration of response <8 months. In a later-lines setting, RR range from 10% to 29% with no complete responses and median duration of response <2 months and median PFS of 2-3 months and OS of 4-5 months [5,208].…”

Section: Treatment Of Local and Disseminated Recurrencesmentioning

confidence: 99%

“…The incidence is increasing steeply, most likely due to the aging population, improved recognition, and rising awareness of MCC [3]. The 10-year survival rate is estimated to be around 57% [4,5]. The prevalence in men is 1.5 times higher than in women.…”

Section: Introductionmentioning

confidence: 99%

Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies

Stachyra

Dudzisz-Śledź

Bylina

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is an uncommon and highly aggressive skin cancer. It develops mostly within chronically sun-exposed areas of the skin. MCPyV is detected in 60–80% of MCC cases as integrated within the genome and is considered a major risk factor for MCC. Viral negative MCCs have a high mutation burden with a UV damage signature. Aberrations occur in RB1, TP53, and NOTCH genes as well as in the PI3K-AKT-mTOR pathway. MCC is highly immunogenic, but MCC cells are known to evade the host’s immune response. Despite the characteristic immunohistological profile of MCC, the diagnosis is challenging, and it should be confirmed by an experienced pathologist. Sentinel lymph node biopsy is considered the most reliable staging tool to identify subclinical nodal disease. Subclinical node metastases are present in about 30–50% of patients with primary MCC. The basis of MCC treatment is surgical excision. MCC is highly radiosensitive. It becomes chemoresistant within a few months. MCC is prone to recurrence. The outcomes in patients with metastatic disease are poor, with a historical 5-year survival of 13.5%. The median progression-free survival is 3–5 months, and the median overall survival is ten months. Currently, immunotherapy has become a standard of care first-line therapy for advanced MCC.

show abstract

“…In both Europe and the United States, approximately 2,500 new cases of MCC are diagnosed each year and metastatic disease is diagnosed in 5-12% of patients [4,5]. Population ageing in the 21 st century is predicted to have a major impact on MCC incidence, which is estimated to reach 3,284 cases in 2025 [3,6,7].…”

Section: Introductionmentioning

confidence: 99%